Drugs / Propranolol
Propranolol
also known as
Propranolol Hydrochloride · Inderal · Inderal LA · PPL · prop · .beta.-propranolol · Anaprilin · Angilol · +68 more
Small molecule targets ADRB1, ADRB2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Hemangiol | — | 2014-04-23 | europa.eu ↗ |
| Label expansions (3) | US (FDA) | INDERAL LA | — | 1984-01-09 – 1987-03-18 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | INDERAL | — | 1979-01-17 – 1986-10-31 | fda.gov ↗ |
| Approved | US (FDA) | INDERAL | — | 1967-11-13 | fda.gov ↗ |
Trials 225 · started per year
today
US approved 1967
EU approved 2014
2
1
1
1
2
1
2
4
4
6
7
8
5
5
16
6
11
7
8
10
12
11
12
5
8
10
8
15
13
12
11
196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 014 trials | ||||||
| Phase 0 | NCT07271485 | Dec 2025 → Dec 2026 expected | hyperacusis | Bloom Mental Health, LLC | Recruiting | No outcome recorded |
| Phase 0 | NCT06787066 | Jul 2025 → Dec 2026 expected | — | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 0 | NCT06066710 | Jan 2025 → Dec 2026 expected | primary progressive aphasia | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 0 | NCT06719804 | Dec 2024 → Dec 2027 expected | epilepsy | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06417177 | Jun 2024 → Dec 2026 expected | — | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 0 | NCT05928689 | Jun 2023 → Sep 2024 | hyperacusis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 0 | NCT05256069 | Apr 2023 → Jul 2025 | — | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 0 | NCT05219799 | Mar 2023 → Jun 2026 overdue | isoproterenol-mediated vasodilatation, obesity disorder | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 0 | NCT03245554 | May 2018 → Sep 2020 | digestive system cancer | Central South University | Unknown | No outcome recorded |
| Phase 0 | NCT02871349 | Aug 2016 → Aug 2020 | autism spectrum disorder | University of Missouri-Columbia | Completed | No outcome recorded |
| Phase 0 | NCT02596776 | Mar 2016 → Aug 2018 | metabolic syndrome X, obesity disorder, prediabetes syndrome | Philip Kern | Completed | No outcome recorded |
| Phase 0 | NCT01988883 | Oct 2014 → Dec 2026 expected | postural orthostatic tachycardia syndrome | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02013492 | Jan 2014 → Jun 2015 | hepatocellular carcinoma, male breast carcinoma, melanoma, ovarian carcinoma +1 | William Carson | Completed | No outcome recorded |
| Phase 0 | NCT01504126 | Mar 2012 → Aug 2019 | fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma +7 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 126 trials | ||||||
| Phase 1 | NCT06670976 | May 2026 → Nov 2029 | soft tissue sarcoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT07528235 | May → Oct 2026 expected | intracerebral hemorrhage, lung disorder | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07353294 | Jan 2026 → Dec 2028 expected | metastatic malignant neoplasm in the lymph nodes, urothelial carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT05979818 | Nov 2024 → Aug 2025 overdue | non-small cell lung carcinoma | Second Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| Phase 1 | NCT05968690 | Sep 2023 → Sep 2026 overdue | melanoma | Sarah Weiss | Recruiting | No outcome recorded |
| Phase 1 | NCT03882255 | Mar → Aug 2019 | — | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 1 | NCT03523650 | Feb 2018 → Jan 2019 | cerebral cavernous malformation | University of Virginia | Unknown | No outcome recorded |
| Phase 1 | NCT03270644 | Aug → Nov 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02897986 | Jan 2017 → Jan 2020 | childhood malignant neoplasm | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 1 | NCT01978457 | Oct 2012 → Dec 2019 | cocaine dependence | Yale University | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01535495 | Feb 2012 → Dec 2015 | proliferative diabetic retinopathy | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT01263197 | Dec 2010 → Mar 2011 | major depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01308944 | Aug 2010 → Aug 2014 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01087749 | Mar 2010 → Dec 2012 | chronic kidney disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01284868 | Jul → Nov 2009 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT00687700 | Mar → May 2008 | chronic obstructive pulmonary disease | Theravance Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT00688805 | Dec 2007 → Dec 2013 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Terminated | No outcome recorded |
| Phase 1 | NCT00549120 | Aug → Oct 2007 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00270959 | Jun 2006 → Sep 2010 | post-traumatic stress disorder | University of Washington | Completed | No outcome recorded |
| Phase 1 | NCT02256722 | Oct → Nov 2005 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00647608 | Sep → Oct 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00652600 | Sep → Dec 2005 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864747 | May 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00865215 | Apr 2005 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00251602 | Mar 2003 → Aug 2012 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1 | NCT02264093 | Nov 1999 → Feb 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/26 trials · 1 missed | ||||||
| Phase 1/2 | NCT03633747 | Jul 2018 → Aug 2020 | liver hemangioma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Terminated | No outcome recorded |
| Phase 1/2 | NCT03384836 | Jan 2018 → May 2027 | cutaneous melanoma | Roswell Park Cancer Institute | Suspended | No outcome recorded |
| Phase 1/2 | NCT02732678 | May 2016 → May 2018 | angiosarcoma | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 1/2 | NCT01238471 | May 2010 → May 2012 | retinopathy of prematurity | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 1/2 | NCT00174902 | Oct 2003 → Aug 2004 | arteriosclerosis disorder | Swiss Federal Institute of Technology | Unknown | No outcome recorded |
| Phase 1/2 | NCT00262470 | Apr 1997 → Dec 2029 expected | cardiac rhythm disease | Satish R. Raj | Active not recruiting | Missed primary |
| Phase 282 trials · 4 met primary · 10 missed | ||||||
| Phase 2 | NCT07836712 | Nov 2026 → Nov 2027 expected | hepatocellular carcinoma, metastatic melanoma | University of Southern California | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07452978 | Sep 2026 → Oct 2027 expected | post-traumatic stress disorder | University Hospital, Tours | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05797662 | Aug 2026 → Sep 2028 expected | Kaposi's sarcoma | AIDS Malignancy Consortium | Recruiting | No outcome recorded |
| Phase 2 | NCT07549906 | Apr → Jul 2026 overdue | malignant colon neoplasm | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07091279 | Jan 2026 → Nov 2028 expected | autism spectrum disorder, disruptive behavior disorder | Jeremy Veenstra-vanderweele | Recruiting | No outcome recorded |
| Phase 2 | NCT06445166 | Aug 2025 → Feb 2028 expected | Kaposi's sarcoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07125391 | Jun 2025 → Aug 2026 overdue | ovarian carcinoma | Bai-Rong Xia | Recruiting | No outcome recorded |
| Phase 2 | NCT06839144 | Mar 2025 → Aug 2026 overdue | ovarian cancer | Tel-Aviv Sourasky Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06775080 | Dec 2024 → Dec 2026 expected | digestive system neoplasm | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04921982 | Oct 2024 → Mar 2025 | post-traumatic stress disorder | Rennes University Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT05741164 | Sep 2024 → Jun 2028 expected | female breast carcinoma, triple-negative breast carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT06145074 | Mar 2024 → Dec 2026 expected | pancreatic ductal adenocarcinoma | Zealand University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06120140 | Feb 2024 → May 2027 expected | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 2 | NCT05692271 | Jul 2023 → Mar 2025 | alcohol-related disorders, post-traumatic stress disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 2 | NCT05451043 | Jul 2023 → Oct 2026 expected | cholangiocarcinoma, hepatocellular carcinoma, malignant pancreatic neoplasm | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
| Phase 2 | NCT05651594 | Mar 2023 → Mar 2029 expected | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05679193 | Jan → Nov 2023 | prostate cancer | Oslo University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03083431 | Sep 2022 → Dec 2028 expected | retinopathy of prematurity | University of Zurich | Recruiting | No outcome recorded |
| Phase 2 | NCT05375240 | Jun 2022 → Jun 2024 | ischemic stroke | Tianjin Medical University General Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05085782 | Feb 2022 → Dec 2024 | fibromyalgia | University of Sherbrooke | Completed | No outcome recorded |
| Phase 2 | NCT05961761 | Aug 2021 → Jan 2028 expected | angiosarcoma, undifferentiated pleomorphic sarcoma | Niels Junker | Recruiting | No outcome recorded |
| Phase 2 | NCT04950426 | Aug 2021 → Jan 2025 | fibromyalgia, post-traumatic stress disorder | Centre Hospitalier Henri Laborit | Completed | No outcome recorded |
| Phase 2 | NCT04982211 | Aug 2021 → Dec 2023 | acute stress disorder, adjustment disorder, post-traumatic stress disorder | Douglas Mental Health University Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04848519 | May 2021 → Oct 2025 overdue | renal pelvis urothelial carcinoma, ureter cancer, urethra transitional cell carcinoma, urinary bladder carcinoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04682158 | Apr 2021 → Apr 2029 expected | esophageal adenocarcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT04047355 | Feb 2021 → Sep 2023 | autism spectrum disorder, developmental disability, disruptive behavior disorder, stereotypic movement disorder | Rutgers, The State University of New Jersey | Completed | Missed primary |
| Phase 2 | NCT04684667 | Jan → Dec 2021 | hemangioma | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT04421209 | Dec 2020 → Jun 2021 | intervertebral disk degenerative disorder, lumbar disk disease | Duke University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04580342 | Oct 2020 → Jan 2021 | hypotensive disorder | Ahmed talaat ahmed aly | Unknown | No outcome recorded |
| Phase 2 | NCT04493489 | Sep 2020 → Sep 2023 | urinary bladder cancer | Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT04518124 | Dec 2019 → Oct 2023 | angiosarcoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT04005365 | Nov 2019 → Jun 2020 | gastric cancer | Yijing He | Unknown | No outcome recorded |
| Phase 2 | NCT03108300 | Aug 2019 → Aug 2020 | soft tissue sarcoma | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT03152786 | Jan 2019 → Jun 2021 | prostate carcinoma | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT03588754 | Sep 2018 → Aug 2027 | alcohol-related disorders | Yale University | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT03323710 | Sep 2018 → Dec 2019 | renal cell carcinoma | Military Institute od Medicine National Research Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03589014 | Apr 2018 → Oct 2021 | cerebral cavernous malformation | Mario Negri Institute for Pharmacological Research | Completed | Met primary |
| Phase 2 | NCT03474614 | Jan 2018 → Feb 2021 | cerebral cavernous malformation | St. Joseph's Hospital and Medical Center, Phoenix | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03348683 | Dec 2017 → Dec 2018 | indomethacin embryofetopathy | Icahn School of Medicine at Mount Sinai | Completed | Missed primary |
| Phase 2 | NCT03161964 | Oct 2017 → Dec 2019 | type 1 diabetes mellitus | Anu Sharma | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02595996 | Jun 2017 → Oct 2020 | primary lymphedema | Columbia University | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03152175 | Mar 2017 → Mar 2022 | acute stress disorder, adjustment disorder, post-traumatic stress disorder | Douglas Mental Health University Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03038295 | Mar 2017 → Dec 2018 | retinopathy of prematurity | Guangdong Women and Children Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01988831 | Jun 2016 → Jan 2022 | cutaneous melanoma | University Hospital, Geneva | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT02631694 | Apr 2016 → Sep 2018 | panic disorder | VU University of Amsterdam | Unknown | No outcome recorded |
| Phase 2 | NCT02620579 | Jan 2016 → Nov 2021 | — | Duke University | Completed | Missed primary |
| Phase 2 | NCT02596867 | Sep 2015 → May 2017 | breast cancer | Texas Tech University Health Sciences Center, El Paso | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02420223 | Jul 2015 → Jul 2018 | plasma cell myeloma | Medical College of Wisconsin | Completed | Met primary |
| Phase 2 | NCT02504944 | Jul 2015 → Aug 2018 | retinopathy of prematurity | Meyer Children's Hospital IRCCS | Completed | Met primary |
| Phase 2 | NCT02104011 | May 2015 → Nov 2017 | kidney angiomyolipoma, tuberous sclerosis | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 2 | NCT02511483 | May 2015 → Nov 2016 | — | McGill University Health Centre/Research Institute of the McGill University Health Centre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01950520 | Feb 2014 → Dec 2022 | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT02014454 | Nov 2013 → Aug 2014 | retinopathy of prematurity | Meyer Children's Hospital IRCCS | Completed | Missed primary |
| Phase 2 | NCT01857817 | Jun 2013 → Apr 2016 | prostate neoplasm | Vicus Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01705392 | Jan 2013 → Feb 2017 | metastatic melanoma | Haukeland University Hospital | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01713556 | Nov 2012 → May 2017 | post-traumatic stress disorder | University Hospital, Toulouse | Completed | Missed primary |
| Phase 2 | NCT01847001 | Oct 2012 → Dec 2018 | breast cancer | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT01784250 | Aug 2012 → Apr 2013 | anxiety | CES University | Unknown | No outcome recorded |
| Phase 2 | NCT01544634 | Apr 2012 → May 2013 | asthma | University of Dundee | Completed | Missed primary |
| Phase 2 | NCT01512173 | Jan 2012 → May 2013 | hemangioma | Pierre Fabre Dermatology | Completed | No outcome recorded |
| Phase 2 | NCT01634347 | Jan 2012 → May 2014 | substance dependence | Douglas Mental Health University Institute | Completed | No outcome recorded |
| Phase 2 | NCT01322048 | Aug 2011 → Jan 2015 | traumatic brain injury | Vanderbilt University | Completed | Missed primary |
| Phase 2 | NCT01349439 | Mar 2011 → Jan 2015 | post-traumatic stress disorder | Douglas Mental Health University Institute | Unknown | No outcome recorded |
| Phase 2 | NCT01265576 | Dec 2010 → Feb 2014 | hepatocellular carcinoma | Vicus Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT01077921 | Jun 2010 → Dec 2013 | sickle cell disease | Laura M. De Castro, MD | Completed | No outcome recorded |
| Phase 2 | NCT01202110 | Jun 2010 → Feb 2015 | traumatic brain injury | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01074853 | May 2010 → Mar 2012 | asthma | University of Dundee | Completed | Missed primary |
| Phase 2 | NCT01074437 | Feb 2010 → Feb 2012 | hemangioma | Seattle Children's Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01007084 | Oct 2009 → Jul 2010 | — | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00934947 | Jul 2009 → Feb 2011 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT00967226 | Jul 2009 → Jan 2013 | hemangioma | Nancy Bauman | Terminated | Missed primary |
| Phase 2 | NCT00611871 | Sep 2007 → Aug 2015 | post-traumatic stress disorder | Wayne State University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00465608 | Apr 2007 → Nov 2008 | post-traumatic stress disorder | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 2 | NCT01080677 | Jan 2007 → Sep 2009 | migraine disorder | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00356187 | Feb 2006 → Jan 2009 | brain injury | Denver Health and Hospital Authority | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00653120 | May → Nov 2005 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00093860 | Oct 2004 → Mar 2005 | syncope, familial vasovagal | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00315913 | Jan 2004 → Mar 2008 | dystocia | University of California, Irvine | Withdrawn | No outcome recorded |
| Phase 2 | NCT00069355 | Sep 2003 → Oct 2004 | acute stress disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT00016666 | May 2001 → Jan 2007 | seasonal affective disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT00158132 | Sep 1999 → Mar 2005 | cocaine dependence | University of Pennsylvania | Completed | Missed primary |
| Phase 2 | NCT00000197 | Jan 1987 → Jan 2002 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2/313 trials · 2 met primary | ||||||
| Phase 2/3 | NCT06798363 | Jan 2025 → Sep 2026 overdue | hemangioma | West China Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05419193 | Feb 2023 → Dec 2024 | intracerebral hemorrhage | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03254186 | Sep 2017 → Feb 2019 | tardive dyskinesia | Emory University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03151681 | Nov 2015 → Sep 2020 | adjustment disorder, post-traumatic stress disorder | Douglas Mental Health University Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT02268357 | Nov 2014 → Dec 2018 | — | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 2/3 | NCT01205074 | Sep 2010 → ? | cirrhosis of liver | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 2/3 | NCT01127568 | Feb → Sep 2010 | post-traumatic stress disorder | Douglas Mental Health University Institute | Unknown | Met primary |
| Phase 2/3 | NCT01058317 | Jan → Sep 2010 | recurrent respiratory papillomatosis | Massachusetts Eye and Ear Infirmary | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01079715 | Jan 2010 → Oct 2012 | retinopathy of prematurity | Meyer Children's Hospital IRCCS | Completed | No outcome recorded |
| Phase 2/3 | NCT01056341 | Jan 2010 → May 2012 | hemangioma | Pierre Fabre Dermatology | Completed | Met primary |
| Phase 2/3 | NCT00744185 | Oct 2008 → Apr 2010 | capillary hemangioma | University Hospital, Bordeaux | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00675714 | Jan 2004 → Sep 2018 | — | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 2/3 | NCT00673309 | Jul 2000 → Apr 2011 | — | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 316 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT06870370 | Sep 2025 overdue | intracranial hypertension, traumatic brain injury | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06863558 | May 2025 → Mar 2026 overdue | intracerebral hemorrhage | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06863571 | Apr 2025 → Mar 2026 overdue | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 3 | NCT06361446 | Mar 2024 → Mar 2025 | migraine disorder | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 3 | NCT04985344 | Feb 2023 → Sep 2027 expected | post-traumatic stress disorder | University Hospital, Toulouse | Recruiting | No outcome recorded |
| Phase 3 | NCT05851781 | Jun 2022 → Jul 2023 | migraine disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT04467086 | Jan 2021 → Nov 2022 | COVID-19 | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT04113187 | Jun 2020 → May 2022 | hereditary hemorrhagic telangiectasia | University Hospital, Bordeaux | Terminated | No outcome recorded |
| Phase 3 | NCT04704947 | Oct 2017 → Oct 2030 expected | poisoning | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT02789982 | May 2016 → Dec 2019 | post-traumatic stress disorder | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT01743885 | Nov 2012 → Jun 2015 | hemangioma | University Hospital, Montpellier | Terminated | No outcome recorded |
| Phase 3 | NCT00390546 | Oct 2006 → Aug 2010 | — | University of British Columbia | Completed | Missed primary |
| Phase 3 | NCT00236561 | Apr 2001 → Dec 2002 | migraine with aura, migraine without aura | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Met primary |
| Phase 3 | NCT00000493 | Sep 1977 → Dec 1985 | coronary artery disorder, myocardial infarction, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000492 | Sep 1977 → Oct 1981 | coronary artery disorder, myocardial infarction, myocardial ischemia, sudden cardiac arrest +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00337740 | — | cirrhosis of liver, esophageal varices | University of Padova | Terminated | No outcome recorded |
| Phase 435 trials · 3 met primary · 4 missed | ||||||
| Phase 4 | NCT07665177 | Jul 2026 → Dec 2027 expected | capillary infantile hemangioma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07583134 | May 2026 → May 2028 expected | breast cancer, myocardial disorder | Chang-Ik Yoon | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05587361 | Nov 2024 → Mar 2027 expected | nicotine dependence | University of Oklahoma | Recruiting | No outcome recorded |
| Phase 4 | NCT06263452 | May 2024 → May 2026 overdue | cardiovascular disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 4 | NCT05585125 | Feb 2024 → Jul 2026 overdue | diastolic heart failure | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05019027 | Jan 2024 → Mar 2026 overdue | amyloidosis, heart disorder | Weill Medical College of Cornell University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05997732 | Oct 2023 → Dec 2027 expected | — | University of Alberta | Recruiting | No outcome recorded |
| Phase 4 | NCT05853627 | Jun 2023 → Jul 2026 overdue | post-traumatic stress disorder | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05479123 | Jun 2022 → Mar 2025 | hemangioma | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04508244 | Dec 2020 → Dec 2024 | acute stress disorder, traumatic brain injury | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT03652922 | Sep 2018 → Nov 2019 | post-traumatic stress disorder | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03309943 | Jan 2018 → Jul 2019 | — | Duke University | Completed | Mixed |
| Phase 4 | NCT03379181 | Jul 2017 → Feb 2020 | hyperthyroidism | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 4 | NCT02790736 | Jun 2016 → Oct 2020 | social phobia | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 4 | NCT02972554 | Jan 2016 → Oct 2017 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT02957331 | Jan 2016 → May 2018 | traumatic brain injury | University of Tennessee | Completed | No outcome recorded |
| Phase 4 | NCT02153944 | Jun 2014 → Oct 2021 | anxiety disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT02111369 | May → Oct 2014 | essential tremor | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02032758 | Jan 2014 → Jan 2015 | dystonia, focal, task-specific | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT02495883 | Dec 2013 → Apr 2017 | essential tremor | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT02740166 | Jun 2013 → Jan 2018 | esophageal varices | Kaohsiung Veterans General Hospital. | Unknown | Met primary |
| Phase 4 | NCT01908972 | Jun 2013 → May 2015 | hemangioma | Seoul National University Hospital | Completed | Met primary |
| Phase 4 | NCT01555554 | May 2012 → Jun 2018 | post-traumatic stress disorder | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01655303 | Feb → Dec 2011 | atrial fibrillation | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01070225 | Mar → Aug 2010 | asthma | University of Dundee | Completed | Missed primary |
| Phase 4 | NCT01059396 | Jan 2010 → Jul 2015 | esophageal varices, hepatic encephalopathy, infectious peritonitis, portal hypertension | Sant Pau Research Institute | Completed | Met primary |
| Phase 4 | NCT01451658 | Dec 2009 → Jul 2020 | esophageal varices with bleeding, hepatocellular carcinoma | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT00862095 | Jun 2008 → Apr 2013 | headache disorder | Madigan Army Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00645450 | Apr 2008 → Jul 2010 | post-traumatic stress disorder | VA Office of Research and Development | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00709735 | May 2007 → Feb 2010 | post-traumatic stress disorder | Massachusetts General Hospital | Completed | Missed primary |
| Phase 4 | NCT01060111 | Jul 2006 → Jul 2008 | migraine disorder | Janssen Korea, Ltd., Korea | Completed | Missed primary |
| Phase 4 | NCT00241904 | May 2006 → May 2010 | atherosclerosis, coronary artery disorder, diabetes mellitus, hypertensive disorder +1 | Johns Hopkins University | Completed | Mixed |
| Phase 4 | NCT00158262 | Sep 2004 → May 2008 | post-traumatic stress disorder | Massachusetts General Hospital | Completed | Missed primary |
| Phase 4 | NCT00060866 | May 2003 → Mar 2005 | neurally mediated hypotension | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 4 | NCT00188045 | Apr 1995 → Dec 2003 | alcoholic liver cirrhosis | University Hospital, Angers | Terminated | No outcome recorded |
| Phase not applicable33 trials | ||||||
| — | NCT07311915 | Jan 2026 → Sep 2028 expected | prostate cancer | Zhongda Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07354126 | Sep 2025 → Feb 2026 overdue | migraine disorder | Muhammad Aamir Latif | Recruiting | No outcome recorded |
| — | NCT06960850 | Jun → Dec 2025 overdue | — | Federal Teaching Hospital Abakaliki | Not yet recruiting | No outcome recorded |
| — | NCT06034158 | Sep 2023 → Mar 2024 | — | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| — | NCT05692869 | Jan → Apr 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT05424016 | Jan 2023 → Nov 2026 expected | hemangioblastoma, von Hippel-Lindau disease | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| — | NCT05525416 | Jul 2022 → Feb 2023 | — | University of Alberta | Completed | No outcome recorded |
| — | NCT05312255 | Jun 2022 → Jun 2027 expected | smoldering plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| — | NCT05429970 | Jun 2022 → Jun 2027 expected | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| — | NCT04682184 | Jan → Mar 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| — | NCT07180043 | Jan 2021 → Jan 2023 | migraine disorder | Kayseri University | Completed | No outcome recorded |
| — | NCT05805553 | Dec 2020 → Sep 2023 | disease of bone structure | King Edward Medical University | Unknown | No outcome recorded |
| — | NCT04513509 | Oct 2020 → Jun 2022 | atrial fibrillation | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT04208776 | Feb 2020 → Dec 2021 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT03388957 | Jul 2018 → Oct 2019 | — | Damascus University | Completed | No outcome recorded |
| — | NCT03524066 | Apr → Dec 2018 | — | Fraunhofer-Institute of Toxicology and Experimental Medicine | Completed | No outcome recorded |
| — | NCT03171805 | Jun 2017 → May 2022 | cirrhosis of liver, portal hypertension | West China Hospital | Unknown | No outcome recorded |
| — | NCT02414451 | Sep 2016 | autism | University of Missouri-Columbia | Withdrawn | No outcome recorded |
| — | NCT02977000 | May 2016 → Mar 2018 | retinopathy of prematurity | Huiqing Sun | Unknown | No outcome recorded |
| — | NCT05327309 | May 2015 → May 2017 | hemangioma | Shaheed Zulfiqar Ali Bhutto Medical University | Completed | No outcome recorded |
| — | NCT02923336 | May 2015 → Jan 2019 | cirrhosis of liver | ALDO TORRE DELGADILLO | Unknown | No outcome recorded |
| — | NCT02484573 | May 2015 → Jan 2020 | cirrhosis of liver | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Unknown | No outcome recorded |
| — | NCT02428205 | Apr 2015 → Nov 2022 | autism | University of Missouri-Columbia | Completed | No outcome recorded |
| — | NCT00502684 | Jun 2014 → Jan 2016 | female breast carcinoma | Kaplan Medical Center | Unknown | No outcome recorded |
| — | NCT01902966 | Sep 2013 → Aug 2020 | cervical cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01333150 | Aug 2011 → Sep 2012 | myofascial pain syndrome, temporomandibular joint disorder | University of Aarhus | Unknown | No outcome recorded |
| — | NCT01319214 | Mar 2011 → Mar 2015 | cocaine dependence | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| — | NCT01299753 | Feb 2011 → Dec 2022 | — | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
| — | NCT00770484 | Nov 2008 → May 2015 | orthostatic hypotension, postural orthostatic tachycardia syndrome | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00759005 | Mar 2007 → Jun 2008 | heroin dependence | National Institute on Drug Dependence, China | Completed | No outcome recorded |
| — | NCT00654290 | Mar 2007 → Jan 2008 | atrial fibrillation | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT00578617 | Sep 2006 → Feb 2009 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00905996 | Aug 2006 → Jan 2009 | cirrhosis of liver | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| Comparator or background therapy139 trials | ||||||
| Phase 0 | NCT06621004 Comparator | Aug → Dec 2024 overdue | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06262061 Comparator | Mar 2024 → Apr 2025 | traumatic brain injury | London Health Sciences Centre | Unknown | No outcome recorded |
| Phase 0 | NCT04833218 Comparator | Jan 2020 → Jun 2021 | traumatic brain injury | Minia University | Unknown | No outcome recorded |
| Phase 0 | NCT03079921 Comparator | Jan 2017 → Apr 2019 | hypoglycemia, type 1 diabetes mellitus | University of Pennsylvania | Completed | No outcome recorded |
| Phase 0 | NCT02467400 Comparator | Jul 2015 → Oct 2017 | postmenopausal osteoporosis | Mayo Clinic | Completed | No outcome recorded |
| Show all 139 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-01-13 | Lupin Limited | Regulatory Lupin Receives Approval from U.S. FDA for Propranolol Hydrochloride Extended-Release Capsules USP lupin.com ↗ |
| 2023-10-26 | GPCR Therapeutics, Inc. | Results GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100 gpcr.co.kr ↗
Importantly, when combined with propranolol, GPC-100-induced HSC mobilization increases by another 2-fold. |
| 2019-09-13 | Lupin Limited | Regulatory Lupin Receives Health Canada Approval for Propranolol Hydrochloride ER Capsules lupin.com ↗
Mumbai, Canada: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Propranolol Hydrochloride Extended-Release (ER) Capsules, 60 mg, 80 mg, 120 mg and 160 mg from Health Canada. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-01-13 | Lupin Limited | Lupin Receives Approval from U.S. FDA for Propranolol Hydrochloride Extended-Release Capsules USP lupin.com ↗ |
| 2023-10-26 | GPCR Therapeutics, Inc. | GPCR Therapeutics Announces Publication on Improving Hematopoietic Stem Cell Mobilization Using Propranolol with GPC-100 gpcr.co.kr ↗ |
| 2023-08-29 | Lupin Limited | Lupin Launches Propranolol Long-Acting Capsules to Improve Heart Health in Canada lupin.com ↗ |
| 2019-09-13 | Lupin Limited | Lupin Receives Health Canada Approval for Propranolol Hydrochloride ER Capsules lupin.com ↗ |
Evidence & citations 82 cited values
Every value below carries the sentence it was read from. 369 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | propranolol | “The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating...” NCT02641314 ↗355“Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline,...” NCT01347541 ↗ “Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine; sertraline;...” NCT00270959 ↗ “There is evidence that the non-selective beta-blocker (NSBB) propranolol reduces intestinal permeability and decreases bacterial translocation in cirrhotic patients,...” NCT02484573 ↗ “Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond...” NCT06863558 ↗ “Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker: Atenolol 25 mg daily, Bisoprolol 2.5 mg daily or Metoprolol 50 mg.” NCT07405229 ↗ “The aim of the study was to compare the clinical efficacy of acebutolol (10mg/Kg/jour) and propranolol (3mg/Kg/j) on the proliferative phase of infantile hemangioma in infants.” NCT01743885 ↗ “Significant reduction of portal pressure is observed in up to 50% of patients treated with propranolol and up to 75% with carvedilol.” NCT07111221 ↗ “Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed” NCT02596867 ↗ |
| Known as | .beta.-propranolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Anaprilin | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Angilol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Apsolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | AVLOCARDYL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01239173 ↗ |
| Known as | AY 64043 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Bedranol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Bedranol s.r. | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Beprane | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Berkolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Beta-prograne mr | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Betadur cr | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Betalong | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Cardinol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Caridolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Deralin | “Propranolol (Deralin) - patients will receive a low dose of 40 mg/day (4X10mg) starting two days before surgery” NCT00502684 ↗ |
| Known as | Dl-propranolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Dociton | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Dupromex | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Euprovasin | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Half beta-prograne mr | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Half propanix la | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Half propatard la | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Half-beprane cr | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Half-betadur cr | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Half-inderal la | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Hemangeol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | HEMANGIOL | “administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination” NCT02897986 ↗ |
| Known as | ICI 45520 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Inderal | “will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK)” NCT04208594 ↗6“Propranolol Inderal (registered trademark) is a Food and Drug Administration-approved drug that belongs to a class of drugs called beta-blockers.” NCT00060866 ↗ “the addition of a beta-blocker such as Propranolol (Inderal) is tolerable when given with chemotherapy” NCT01308944 ↗ “Propranolol is available in generic form as the Wyeth product under the trade name Inderal.” NCT01127568 ↗ “Propranolol (Inderal) :10-360 mg/day” NCT04320589 ↗ |
| Known as | Inderal (Registered Trademark) | “Propranolol (Inderal® (Registered Trademark)) is a Food and Drug Administration-approved drug that belongs to a class of drugs called beta-blockers.” NCT00093860 ↗ |
| Known as | Inderal LA | “Single-Dose Fed Bioequivalence Study of Propranolol Hydrochloride Extended-Release Capsules (160 mg; Mylan) and Inderal® LA Capsules (160 mg; Wyeth) in Healthy Volunteers” NCT00647608 ↗2“On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 6:30 PM, after dinner.” NCT03049306 ↗ “Inderal® LA Capsules 160 mg” NCT00647816 ↗ |
| Known as | Inderal LA 80 | “Beta-blocker medication consists of 80 mg/day of propranolol (Inderal LA 80), aspirin will be given in a dose of 100 mg/day.” NCT00174902 ↗ |
| Known as | Inderalici | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Inderide-40/25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Inderide-80/25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Inderol | “Drug: Inderol (propranolol)” NCT00597389 ↗ |
| Known as | Indobloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Innopran | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Innopran xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Lederpronol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Lopranol la | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Monoprolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | NSC-91523 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Obsidan | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | PPL | “This randomised trial aimed to address whether endoscopic variceal ligation (EVL) or propranolol (PPL) is more effective at preventing initial oesophageal variceal bleeding...” PMID 38123994 ↗ Mar 20241“We aimed to evaluate the safety and efficacy of propranolol (PPL) compared to endoscopic variceal ligation (EVL) for V.H. primary prevention in patients with ascites.” PMID 35672572 ↗ Jun 2022 |
| Known as | PPNL | “The β-adrenergic blocker propranolol (PPNL) possesses such amnestic properties.” NCT05853627 ↗ |
| Known as | Probeta la | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | prop | “In addition, in cancer cell cultures, catecholamines (norepinephrine and epinephrine) induced an increase of VEGF expression in a tissue culture of nasopharyngeal carcinoma, an...” NCT01238471 ↗1“with propranolol (PROP) as an active control.” PMID 15316798 ↗ Aug 2004 |
| Known as | Propanix la | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Propanix-10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Propanix-160 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Propanix-160 sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Propanix-40 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Propanix-80 | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Propanolol-CT | “one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose)” NCT02509559 ↗ |
| Known as | Propatard la | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Propranolol (slow-Release) | “Name: Propranolol (slow-Release) and Etodolac.” NCT06839144 ↗ |
| Known as | Propranolol Hcl | “Drug: Propranolol Hcl 40mg Tab” NCT04421209 ↗ |
| Known as | Propranolol Hydrochloride | “will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK)” NCT04208594 ↗24“Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated.” NCT00910689 ↗ “drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the "Propranolol" Group and treated with propranolol.” NCT01988831 ↗ “Propranolol hydrochloride is a nonselective beta-adrenergic antagonist that has a known activity in the myometrium.” PMID 33421647 ↗ Jan 2021 “Patients receive propranolol hydrochloride orally (PO) 2 hours prior to standard of care prostatectomy.” NCT03152786 ↗ “Propranolol hydrochloride capsules 160 mg once daily, slow release formulation” NCT00884663 ↗ “Propranolol Hydrochloride Extended-Release Capsules 160 mg” NCT00647816 ↗ “Inderal (propranolol hydrochloride)” NCT01319214 ↗ “Propranolol Hydrochloride 1 MG/ML” NCT06422494 ↗ “Drug: Propranolol Hydrochloride” NCT06787066 ↗ “Drug: Propranolol Hydrochloride” NCT01555554 ↗ |
| Known as | Propranolol hydrochloride (USP/EP) Oral Solution | “Propranolol hydrochloride (USP/EP) Oral Solution” NCT01074437 ↗ |
| Known as | Propranolol hydrochloride intensol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | propranolol hydrochloride-LA | “If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second...” NCT00910689 ↗ |
| Known as | Propranolol LA | “Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.” NCT02620579 ↗ |
| Known as | Proprasylyt | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Pylapron | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Rapranol sr | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Reducor | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Sagittol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Slo-blok | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Slo-pro | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Sloprolol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Sumial | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Syprol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | Tesnol | ChEMBL registry synonym — accepted as the source's own label CHEMBL27 ↗ |
| Known as | V0400 GL 01A | “Pierre Fabre Dermatologie has developed a new formulation of propranolol (V0400 GL 01A) which is a topical gel adapted to paediatric use.” NCT01512173 ↗ |
| Action | Inhibit | “We propose to administer propranolol, a beta-adrenergic receptor blocking medication that is frequently prescribed for the treatment of hypertension, to patients with SAD in the winter.” NCT00016666 ↗2“Beta-1 adrenergic receptor antagonist” CHEMBL27 ↗ “Beta-2 adrenergic receptor antagonist” CHEMBL27 ↗ |
| Modality | Small molecule | “beta-blocker” NCT01908972 ↗ |
| Route | Oral | “treatment with oral propranolol” NCT00060866 ↗ |
| Target | ADRB1 | “Beta-1 adrenergic receptor antagonist” CHEMBL27 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor antagonist” CHEMBL27 ↗ |